| 2.27 -0.16 (-6.58%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.49 | 1-year : | 4.38 |
| Resists | First : | 2.98 | Second : | 3.75 |
| Pivot price | 2.15  |
|||
| Supports | First : | 1.75 | Second : | 1.46 |
| MAs | MA(5) : | 2.2 |
MA(20) : | 2.42 |
| MA(100) : | 1.65 |
MA(250) : | 1.26 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 39.9 |
D(3) : | 30.5 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 4 | Low : | 0.65 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BYSI ] has closed below upper band by 38.7%. Bollinger Bands are 23.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.49 - 2.5 | 2.5 - 2.51 |
| Low: | 2.26 - 2.27 | 2.27 - 2.28 |
| Close: | 2.41 - 2.43 | 2.43 - 2.44 |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Sat, 30 Mar 2024
BeyondSpring Inc. (NASDAQ:BYSI) Short Interest Update - MarketBeat
Mon, 25 Mar 2024
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 ... - Yahoo Finance
Wed, 06 Mar 2024
Should You Hold Beyondspring Inc (BYSI) Stock Wednesday Morning? - InvestorsObserver
Tue, 05 Mar 2024
Do Traders Think Beyondspring Inc (BYSI) Can Keep Climbing Tuesday? - InvestorsObserver
Fri, 01 Mar 2024
BYSI Stock Quote Price and Forecast - CNN
Mon, 26 Feb 2024
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 2.387e+007 (%) |
| Held by Institutions | 26.4 (%) |
| Shares Short | 1,880 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.96e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 541 % |
| Return on Equity (ttm) | -38.7 % |
| Qtrly Rev. Growth | 1.55e+006 % |
| Gross Profit (p.s.) | 172.94 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.85 |
| Dividend | 0 |
| Forward Dividend | 2.37e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|